Unprecedented,” “remarkable” and “transformative” were just a few of the descriptives tossed out by Wall Street analysts in response to Revolution Medicines Inc.’s phase III readout, showing RAS ...

The development of glucagon-like peptide 1 receptor (GLP-1R) agonists, such as semaglutide and tirzepatide, has been a game changer in the clinical management of overweight and obesity, but there is ...

Oricell Therapeutics Holdings Ltd closed a $110 million pre-IPO round to expand its global footprint and advance its lead candidate, a GPC3-targeted autologous CAR T therapy for liver cancer to ...

Armed with a fully subscribed $80 million series D round, Life Biosciences Inc. is making progress with its lead candidate, ER-100, which is in phase I trials testing its theory on reversing the ...

Gilead Sciences Inc. has exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera ...

The U.S. FDA issued a warning letter to Medline Inc. having identified several issues with its Namic brand angiographic control syringes and manifolds used for the intra-arterial or intravenous ...

More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline.

New hires and promotions in the biopharma and med-tech industries, including: Aravax, Impedimed, Latigo, Orano Med, Remedy, Spectral AI, Stealth, Stoke, Supira.

Realta Life Sciences Inc. raised an additional $40 million in the final tranche of its series A investment, bringing the ...

Year-to-date money raised in public, private and other financings of biopharma companies. Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Cookie Settings ...

Everest Medicines Ltd. has agreed to acquire a Singapore-based commercial unit of Hasten Biopharmaceuticals (Asia) Ltd. for $150 million up front, gaining market authorization holder rights to 14 ...

There are new data to chew over in the ongoing controversy about obesity being diagnosed as a disease from a study tracking ...